InMed Pharmaceuticals officer holds 62,273 options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. reports that Brett R. Hagen, its Senior Vice President, Finance and Chief Accounting Officer, directly holds options to purchase 62,273 shares of common stock at an exercise price of $10.37 per share, expiring September 24, 2036. The options were received in the merger effective November 6, 2026, in exchange for options in Pre-Merger Mentari. They vest as to 25% on August 3, 2027, with equal monthly installments thereafter through August 3, 2030, subject to his continued service on each vesting date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) F1, F2 | -- | -- | -- |
Footnotes (2)
- F1. Effective as of November 6, 2026, (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
- F2. Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Mentari held by the Reporting Person prior to the Merger. This option will vest as to 25% on August 3, 2027 and in equal monthly installments thereafter through August 3, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
vesting technical
Stock Option (Right to Buy) technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options does InMed Pharmaceuticals (INM) officer Brett R. Hagen hold?
What is the exercise price of Brett R. Hagen’s InMed (INM) options?
AI-generated analysis. How Rhea-AI works. Not financial advice.